STOCK TITAN
  1. Home
  2. News
  3. IPSC

Century Therapeutics Inc - IPSC STOCK NEWS

Welcome to our dedicated news page for Century Therapeutics (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Century Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Century Therapeutics's position in the market.

News
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit with a fireside chat and panel discussion. The events will focus on iPSC-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences
-
News
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) expands its iPSC-derived iNK cell therapy, CNTY-101, into additional autoimmune disease indications. A $60 million private placement supports this expansion, extending the cash runway into 2026. The acquisition of Clade Therapeutics enhances Century's position in allogeneic, iPSC-derived cell therapy with new pipeline programs in cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
acquisition
-
News
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) presents promising preclinical data at AACR Annual Meeting 2024, showcasing advancements in iPSC-derived cell therapies for immuno-oncology and autoimmune diseases. The data highlights innovative gene editing, protein engineering, and manufacturing capabilities, including a dual-targeting CAR for B cell malignancies and enhanced protection against rejection through Allo-Evasion™ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
clinical trial
News
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. The event will focus on the development of iPSC-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
-
News
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Century Therapeutics, Inc. (NASDAQ: IPSC) reported financial results and key developments for the year 2023. The company presented positive data from the Phase 1 ELiPSE-1 Trial of CNTY-101 in B-cell lymphomas, received IND clearance for CNTY-101 in SLE, and plans to initiate the CALiPSO-1 trial in 2024. Century ended 2023 with $261.8 million in cash and a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
earnings
-
News
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) announces preclinical data presentation at the 2024 AACR Annual Meeting showcasing iPSC-derived cell therapy capabilities in immuno-oncology and autoimmune diseases. The data includes advancements in iPSC reprogramming, gene editing, protein engineering, and computational biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
none
News
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8th, 2024. The event will be available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
News
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) presents initial clinical data at 65th ASH Annual Meeting, demonstrating encouraging results for CNTY-101 in R/R B-cell lymphoma patient. The data indicates potential for a multi-dosing strategy without the need for lymphodepletion, positioning CNTY-101 to fill an unmet need among heavily pretreated non-Hodgkin lymphoma patients. The company plans to advance the study at higher doses and present additional clinical data in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company’s lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. The Company will also present additional results from patients treated at Dose Level 1 (100 million cell dose), as well as preliminary data from patients treated at Dose Level 2 (300 million cell dose). Additionally, Century Therapeutics will discuss its planned Phase 1 trial, including supporting preclinical data, for CNTY-101 in systemic lupus erythematosus, the first autoimmune and inflammatory disease indication for CNTY-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.08%
Tags
conferences clinical trial
News
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) has received clearance from the U.S. FDA for its Phase 1 clinical trial to assess CNTY-101, an iPSC-derived cell therapy, in patients with systemic lupus erythematosus (SLE). This marks the second IND clearance for CNTY-101 and the first for an autoimmune and inflammatory disease indication. CNTY-101 is engineered with six precision gene edits and is designed to address the unmet medical needs of SLE patients. The Phase 1 clinical trial is set to begin in the first half of 2024, with initial data expected by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.08%
Tags
clinical trial
Stock IPSC logo
Century Therapeutics Inc

Nasdaq:IPSC

IPSC Rankings

#3726 Ranked by Market Cap
#5419 Ranked by Stock Gains
N/A Ranked by Dividends

IPSC Stock Data

253.44M
26.36M
36.38%
50.41%
2.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Philadelphia

About IPSC

Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.